Immunologic Resolution of Human Chronic Graft-versus-Host Disease

Citations of this article
Mendeley users who have this article in their library.


To determine the role of regulatory T lymphocytes (Tregs) in the pathogenesis of human chronic graft-versus-host disease (GVHD) and its clinical resolution, we evaluated long-term recipients of pediatric allogeneic hematopoietic stem cell transplantation (HSCT). Seventy-one recipients were evaluated, 30 of whom had a history of chronic GVHD, including 16 with active chronic GVHD and 14 with resolved chronic GVHD. There were no significant clinical differences and no differences in the frequency of Tregs (CD4+, CD127-, CD25+) between the recipients with active chronic GVHD and those with resolved chronic GVHD. Using the Miyara/Sakaguchi classification scheme to identify functional Tregs, a decreased frequency of functional resting Tregs (rTregs) was identified in recipients with active chronic GVHD (P=009 compared with normal donors; P=001 compared with HSCT recipients without history of chronic GVHD; P=005 compared with recipients with resolved chronic GVHD). The frequency and number of recent thymic emigrants in rTregs were normal in recipients with resolved chronic GVHD, but persistently decreased in recipients with active chronic GVHD. These results support the hypothesis that the reestablishment of normal numbers of functional rTregs is required for the clinical resolution of chronic GVHD.




Mahadeo, K. M., Masinsin, B., Kapoor, N., Shah, A. J., Abdel-Azim, H., & Parkman, R. (2014). Immunologic Resolution of Human Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 20(10), 1508–1515.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free